新型TRK激酶小分子抑制剂的筛选与验证
|
摘要
原肌球蛋白相关激酶(Tropomyosin-Related Kinase,TRK)属于受体酪氨酸激酶家族,具有调节细胞增殖、分化、凋亡、代谢等作用.在多种肿瘤细胞中发现TRK激酶编码基因NTRK的融合现象,TRK蛋白过表达或激酶活性组成性激活促进了肿瘤的发生发展.以TRK激酶为靶标的小分子抑制剂正处于研发之中,如Entrectinib等.本研究以Entrectinib为阳性对照,从小分子化合物库中筛选得到Crizotinib、LY2874455等7个新颖的TRK激酶小分子抑制剂,结构计算提示Dovitinib等4个化合物均属于ATP竞争性抑制剂.在NTRK1基因融合的KM12细胞体外增殖实验中,全部的TRK激酶抑制剂均能抑制细胞增殖,且LY2874455最为显著.在细胞的联合用药实验中,发现Crizotinib与Entrectinib的联用具有协同作用.
Tropomyosin-related kinases(TRKs)are a group of receptor tyrosine kinases,which regulate many cellular functions including cell proliferation,cell differentiation,metabolism and apoptosis.Gene fusion of neurotropic tropomyosin receptor kinase genes(NTRK)coding for TRKs contributes to constitutive activation or overexpression of TRKs,which increase the risk of tumor genesis.Up to now,a variety of TRK inhibitors including Entrectinib are under research and development.In this study,7 novel inhibitors against TRKs including Crizotinib,LY2874455 are obtained from a HTRF assay,with Entrectinib as a positive control.Structure calculation demonstrates that Dovitinib and other 3 compounds are ATP competitive inhibitors.All the novel TRK inhibitors show strong suppressive effect on cell proliferative in the colorectal carcinoma cell line KM12 with NTRK1 gene fusion,with LY287445 as the most significant among them.Furthermore,the combination of Crizotinib and Entrectinib was demonstrated to have a synergistic effect on KM12 cell proliferation.
Tropomyosin-related kinases(TRKs)are a group of receptor tyrosine kinases,which regulate many cellular functions including cell proliferation,cell differentiation,metabolism and apoptosis.Gene fusion of neurotropic tropomyosin receptor kinase genes(NTRK)coding for TRKs contributes to constitutive activation or overexpression of TRKs,which increase the risk of tumor genesis.Up to now,a variety of TRK inhibitors including Entrectinib are under research and development.In this study,7 novel inhibitors against TRKs including Crizotinib,LY2874455 are obtained from a HTRF assay,with Entrectinib as a positive control.Structure calculation demonstrates that Dovitinib and other 3 compounds are ATP competitive inhibitors.All the novel TRK inhibitors show strong suppressive effect on cell proliferative in the colorectal carcinoma cell line KM12 with NTRK1 gene fusion,with LY287445 as the most significant among them.Furthermore,the combination of Crizotinib and Entrectinib was demonstrated to have a synergistic effect on KM12 cell proliferation.
引文
[1]WILLIAM D S.Functions of the neurotrophins during nervous system development:What the knock-outs are teaching us[J].Cell,1994,77(5):627-638.
[2]MARTIN Z D,HUGHES S H,BARBACID M.A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences[J].Nature,1986,319(6056):743-748.
[3]STRANSKY N,CERAMI E,SCHALM,et al.The landscape of kinase fusions in cancer[J].Nat Commun,2014,5:4846.
[4]WANG T,YU D,LAMB M L.Trkkinase inhibitors as new treatments for cancer and pain[J].Expert Opin Ther Pat,2009,19(3):305-319.
[5]KARAMAN M W,HERRGARD S,TREIBER D K,et al.Aquantitative analysis of kinase inhibitor selectivity[J].Nat Biotechnol,2008,26(1):127-132.
[6]SHAW A T,HSU P P,AWAD M M,et al.Tyrosine kinase gene rearrange-ments in epithelial malignancies[J].Nat Rev Cancer,2013,13(11):772-787.
[7]KUMAR V,GUPTA A K,SHUKLA R K,et al.Molecular mechanism of switching of TrkA/p75(NTR)signaling in monocrotophos induced neurotoxicity[J].Sci Rep,2015,10(1):1-17.
[8]BURRIS H A,SHAW A T,BAUER T M,et al.Pharmacokinetics(PK)of LOXO-101during the firstin-human phase I study in patients with advanced solid tumors:Interim update[J].Cancer Res,2015,75(15):4529.
[9]DRILON A,SIENA S,OU S,et al.Safety and antitumor activity of the multitargeted Pan-TRK,ROS1,and ALK inhibitor Entrectinib:Combined results from two phase I trials(ALKA-372-001 and STARTRK-1)[J].Cancer Discov,2017,7(4):400-409.
[10]FARAGO A F,LE L P,ZHENG Z,et al.Durable clinical response to Entrectinib in NTRK1-rearranged non-small cell lung cancer[J].J Thorac Oncol,2015,10(12):1670-1674.
[11]DOEBELE R C,DAVIS L E,VAISHNAVI A,et al.An oncogenic NTRK fusion in a patient with softtissue Sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101[J].Cancer Discov,2015,5(10):1049-1057.
[12]JULIE W,PAUL G,JEFF C,et al.Infantile fibrosarcoma with NTRK3-ETV6fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101[J].Pediatr Blood Cancer,2016,63(8):1468-1470.
[13]VAISHNAVI A,CAPELLETTI M,LE A T,et al.Oncogenic and drug-sensitive NTRK1rearrangements in lung cancer[J].Nat Med,2013,19(11):1469-1472.
[14]ARDINI E,MENICHINCHERI M,BANFI P,et al.Entrectinib,a Pan-TRK,ROS1,and ALKInhibitor with Activity in Multiple Molecularly Defined Cancer Indications[J].Mol Cancer Ther,2016,15(4):628-639.
[15]ARDINI E,BOSOTTI R,BORGIA A L,et al.The TPM3-NTRK1rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRK-A kinase inhibition[J].Mol Oncol,2014,8(8):1495-1507.
[16]SARTORE BIANCHI A,ARDINI E,BOSOTTI R,et al.Sensitivity to Entrectinib associated with a novel LMNA-NTRK1gene fusion in metastatic colorectal cancer[J].J Natl Cancer Inst,2016,108(1):1-6.
[17]李玥,李会娟,王田,等.蛋白激酶的生化活性检测方法研究进展[J].生命的化学,2014,34(5):1-14.
[18]CRANCIER L,VANDENBERGHE I,GOMES B,et al.Chromosomal rearrangements involving the NTRK1gene in colorectal carcinoma[J].Cancer Lett,2015,365(1):107-111.
[19]DRILON A,LI G,DOGAN S,et al.What hides behind the MASC:Clinical response and acquired resistance to Entrectinib after ETV6-NTRK3identification in a mammary analogue secretory carcinoma(MASC)[J].Ann Oncol,2016,27(5):920-926.
[20]WU D,GUO M,PHILIPS M A,et al.Crystal Structure of the FGFR4/LY2874455complex reveals insights into the Pan-FGFR selectivity of LY2874455[J].PLoS One,2016,11(9):1-11.
[2]MARTIN Z D,HUGHES S H,BARBACID M.A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences[J].Nature,1986,319(6056):743-748.
[3]STRANSKY N,CERAMI E,SCHALM,et al.The landscape of kinase fusions in cancer[J].Nat Commun,2014,5:4846.
[4]WANG T,YU D,LAMB M L.Trkkinase inhibitors as new treatments for cancer and pain[J].Expert Opin Ther Pat,2009,19(3):305-319.
[5]KARAMAN M W,HERRGARD S,TREIBER D K,et al.Aquantitative analysis of kinase inhibitor selectivity[J].Nat Biotechnol,2008,26(1):127-132.
[6]SHAW A T,HSU P P,AWAD M M,et al.Tyrosine kinase gene rearrange-ments in epithelial malignancies[J].Nat Rev Cancer,2013,13(11):772-787.
[7]KUMAR V,GUPTA A K,SHUKLA R K,et al.Molecular mechanism of switching of TrkA/p75(NTR)signaling in monocrotophos induced neurotoxicity[J].Sci Rep,2015,10(1):1-17.
[8]BURRIS H A,SHAW A T,BAUER T M,et al.Pharmacokinetics(PK)of LOXO-101during the firstin-human phase I study in patients with advanced solid tumors:Interim update[J].Cancer Res,2015,75(15):4529.
[9]DRILON A,SIENA S,OU S,et al.Safety and antitumor activity of the multitargeted Pan-TRK,ROS1,and ALK inhibitor Entrectinib:Combined results from two phase I trials(ALKA-372-001 and STARTRK-1)[J].Cancer Discov,2017,7(4):400-409.
[10]FARAGO A F,LE L P,ZHENG Z,et al.Durable clinical response to Entrectinib in NTRK1-rearranged non-small cell lung cancer[J].J Thorac Oncol,2015,10(12):1670-1674.
[11]DOEBELE R C,DAVIS L E,VAISHNAVI A,et al.An oncogenic NTRK fusion in a patient with softtissue Sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101[J].Cancer Discov,2015,5(10):1049-1057.
[12]JULIE W,PAUL G,JEFF C,et al.Infantile fibrosarcoma with NTRK3-ETV6fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101[J].Pediatr Blood Cancer,2016,63(8):1468-1470.
[13]VAISHNAVI A,CAPELLETTI M,LE A T,et al.Oncogenic and drug-sensitive NTRK1rearrangements in lung cancer[J].Nat Med,2013,19(11):1469-1472.
[14]ARDINI E,MENICHINCHERI M,BANFI P,et al.Entrectinib,a Pan-TRK,ROS1,and ALKInhibitor with Activity in Multiple Molecularly Defined Cancer Indications[J].Mol Cancer Ther,2016,15(4):628-639.
[15]ARDINI E,BOSOTTI R,BORGIA A L,et al.The TPM3-NTRK1rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRK-A kinase inhibition[J].Mol Oncol,2014,8(8):1495-1507.
[16]SARTORE BIANCHI A,ARDINI E,BOSOTTI R,et al.Sensitivity to Entrectinib associated with a novel LMNA-NTRK1gene fusion in metastatic colorectal cancer[J].J Natl Cancer Inst,2016,108(1):1-6.
[17]李玥,李会娟,王田,等.蛋白激酶的生化活性检测方法研究进展[J].生命的化学,2014,34(5):1-14.
[18]CRANCIER L,VANDENBERGHE I,GOMES B,et al.Chromosomal rearrangements involving the NTRK1gene in colorectal carcinoma[J].Cancer Lett,2015,365(1):107-111.
[19]DRILON A,LI G,DOGAN S,et al.What hides behind the MASC:Clinical response and acquired resistance to Entrectinib after ETV6-NTRK3identification in a mammary analogue secretory carcinoma(MASC)[J].Ann Oncol,2016,27(5):920-926.
[20]WU D,GUO M,PHILIPS M A,et al.Crystal Structure of the FGFR4/LY2874455complex reveals insights into the Pan-FGFR selectivity of LY2874455[J].PLoS One,2016,11(9):1-11.